Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-1,178
Closed -$271K 118
2020
Q4
$271K Buy
1,178
+347
+42% +$80K 0.28% 131
2020
Q3
$211K Buy
+831
New +$206K 0.37% 139
2018
Q1
Sell
-1,567
Closed -$273K 127
2017
Q4
$273K Buy
+1,567
New +$277K 1.13% 29
2017
Q3
Sell
-1,190
Closed -$205K 149
2017
Q2
$205K Buy
+1,190
New +$194K 0.47% 116
2016
Q1
Sell
-4,271
Closed -$693K 196
2015
Q4
$693K Buy
4,271
+1,326
+45% +$208K 0.57% 27
2015
Q3
$407K Buy
+2,945
New +$464K 0.14% 77
2015
Q1
Sell
-2,314
Closed -$364K 199
2014
Q4
$369K Buy
+2,314
New +$361K 0.15% 94
2014
Q3
Sell
-3,321
Closed -$434K 195
2014
Q2
$393K Buy
+3,321
New +$384K 0.19% 93

Other funds holding AMGN

QCM Cayman's AMGN Position: Q1 2021 in Review

QCM Cayman sold out of Amgen (AMGN) in Q1 2021, closing a stake of 1,178 shares — an estimated $271K sold.

QCM Cayman first reported a position in AMGN in Q2 2014 and held it in 8 quarters. The position peaked at $693K in Q4 2015. 2,219 funds tracked by Wall St. Rank hold AMGN as of Q1 2021.

  • QCM Cayman reported no remaining Amgen position as of Q1 2021 after selling out during the quarter.
  • QCM Cayman sold 1,178 Amgen shares in Q1 2021, an estimated $271K.
  • QCM Cayman first reported a position in Amgen in Q2 2014 and held it in 8 quarters.
  • QCM Cayman's Amgen position peaked at $693K in Q4 2015.
  • 2,219 funds tracked by Wall St. Rank held Amgen as of Q1 2021.

Based on QCM Cayman's 13F filing for Q1 2021, filed 17 May 2021.